Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUMP-IT
2024-515525-28-00Phase 3Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of floxuridine, fluorouracil, oxaliplatin, irinotecan and folinic acid in colorectal adenocarcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Feasibility of HAIP chemotherapy plus systemic chemotherapy. Planned start Nov 2024; status: authorised.
02
Drugs
floxuridinefluorouraciloxaliplatinirinotecanfolinic acid
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on 2024-515525-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515525-28-00.